chufangao/CTO huggingface dataset:
Clinical trial NCT04264637: Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis
Official title: A Randomized, Double-Blind, Placebo Controlled, Crossover Study to Evaluate the Onset of Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in Allergic Rhinitis Sufferers Following Pollen Exposure in an Environmental Exposure Chamber
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 110.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-03
Primary completion date: 2021-03-17
Completion date: 2021-03-17
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT03740737: Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology
Acronym: RITA-1
Sponsor: Ferring Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 579.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-26
Primary completion date: 2020-11-11
Completion date: 2020-11-11
Baseline population: The modified intention-to-treat (mITT) analysis set comprised all randomized and exposed participants. Participants were analyzed according to planned treatment.
Clinical trial NCT04502888: Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
Official title: Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint, SL-172154 (SIRPα-Fc-CD40L), Administered Intratumorally in Subjects With Cutaneous Squamous Cell Carcinoma or Squamous Cell Carcinoma of the Head and Neck
Sponsor: Shattuck Labs, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-17
Primary completion date: 2022-04-08
Completion date: 2022-04-08
Clinical trial NCT02458690: eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
Official title: eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 216.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-31
Primary completion date: 2019-08-31
Completion date: 2021-03-31
Clinical trial NCT02577406: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Official title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
Acronym: IDHENTIFY
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 319.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-30
Primary completion date: 2020-03-17
Completion date: 2024-03-25
Clinical trial NCT02267863: A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Official title: A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Sponsor: Aptose Biosciences Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Drug manufacturing process and procedure review
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-10-31
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Clinical trial NCT04629339: Study of INCB086550 in Select Solid Tumors
Official title: A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-02
Primary completion date: 2024-03-26
Completion date: 2024-03-26
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT05475821: Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants
Official title: A First in Human, Single Ascending Dose Study for the Assessment of Pharmacokinetics, Safety and Tolerability of ABBV-990 in Healthy Male and Female Subjects
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company decision: re-evaluation of risk vs benefit (based on animal data)
Enrollment: 24.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-07-25
Primary completion date: 2022-09-26
Completion date: 2022-09-26
Plan to share individual participant data: NO
Clinical trial NCT05094154: Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
Official title: Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
Acronym: ACORN
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 2634.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-10
Primary completion date: 2022-10-21
Completion date: 2022-10-21
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.
IPD time frame: The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.
IPD access criteria: Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.
Clinical trial NCT05388435: Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Official title: A Phase 1/2, Open-Label, Multicenter, Dose-Finding Study of SKL27969 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy in Patients With Advanced Solid Tumors
Sponsor: SK Life Science, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study has been terminated based on portfolio prioritization. No safety trends or issues were identified at any dose level.
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-12
Primary completion date: 2024-03-01
Completion date: 2024-03-01
Clinical trial NCT04611126: T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Official title: T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer
Sponsor: Herlev Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-22
Primary completion date: 2024-03-03
Completion date: 2024-07-02
Clinical trial NCT02809690: 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
Official title: Pilot Feasibility Study of 18F-FMAU PET for Diagnosing and Characterizing Prostate Cancer
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-09-12
Primary completion date: 2021-07-21
Completion date: 2021-07-21
Clinical trial NCT03382899: Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Official title: A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Acronym: Cypress 1
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The CYPRESS-1 trial was closed early after the planned primary analysis because the risk benefit ratio is unfavorable.
Enrollment: 101.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-19
Primary completion date: 2019-12-06
Completion date: 2020-03-05
Baseline population: All randomized participants.
Limitations and caveats: Study was terminated early after completion of primary analysis; hence, no mature data were available for final analysis.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03837756: Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV
Official title: Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial.
Acronym: TITAN
Sponsor: University of Aarhus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-05-06
Primary completion date: 2022-07-01
Completion date: 2023-05-01
Plan to share individual participant data: YES
IPD sharing description: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan).
IPD time frame: Data will become available following publication of the specific dataset with no planned end date.
IPD access criteria: Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposal should be addressed to olesoega@rm.dk
Clinical trial NCT04131556: A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
Official title: A Phase 1, Open-label, Randomized, Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Subjects
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was stopped because based on the planned interim analysis of the data of Part 1, palatability of both pediatric formulations was not acceptable.
Enrollment: 20.0 (ACTUAL)
Number of arms: 10.0
Start date: 2019-10-25
Primary completion date: 2020-01-06
Completion date: 2020-01-06
Baseline population: Safety set 1 consisted of all participants who received at least 1 dose of maribavir in Part 1.
Limitations and caveats: Sponsor terminated this study based on the planned interim analysis of the data of Part 1, palatability of both pediatric formulations was not acceptable.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT02710669: New Formulations of Propafenone to Treat Atrial Fibrillation
Official title: Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study halted/terminated prematurely due to COVID.
Enrollment: 193.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-10-31
Primary completion date: 2020-03-11
Completion date: 2020-04-30
Baseline population: One participant was not randomized
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04093115: Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Official title: A Clinical Trial to Evaluate the Efficacy and Safety of CX1106 in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma After Failure of or Unfit for Platinum-containing Therapy
Acronym: HNSCC
Sponsor: Beijing Konruns Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study was terminated voluntarily by the sponsor due to changes in clinical development strategy.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-09
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT03895372: A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
Official title: A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 179.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-06-27
Primary completion date: 2020-05-21
Completion date: 2020-11-26
Baseline population: Demographic and baseline characteristics were summarized by randomized treatment group for all randomized and treated participants.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05404919: Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
Official title: Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant Candidates
Acronym: INHIBITOR
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Insufficient enrollment; departure of primary investigator from institution
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-09-06
Primary completion date: 2024-08-01
Completion date: 2024-08-01
Plan to share individual participant data: NO
Clinical trial NCT04420624: COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction
Official title: COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction
Acronym: COLD-MI
Sponsor: University Hospital, Montpellier (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Inclusion period completed
Enrollment: 54.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-04
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Plan to share individual participant data: NO
Clinical trial NCT04167618: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Official title: A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma
Sponsor: Y-mAbs Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business priorities
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-30
Primary completion date: 2022-08-11
Completion date: 2022-08-11
Limitations and caveats: The trial was terminated after 2 subjects due to a business strategy decision. At this point the maximum tolerated dose was not established.
Clinical trial NCT03637842: Lorcaserin for Cannabis Use Disorder
Official title: Randomized Controlled Trial of Lorcaserin for Cannabis Use Disorder
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: terminated due to lorcaserin recall
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-01
Primary completion date: 2020-02-29
Completion date: 2020-02-29
Limitations and caveats: Study was prematurely terminated due to FDA recall of Lorcaserin.
Plan to share individual participant data: NO
Clinical trial NCT02588170: Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Official title: A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors
Sponsor: Hutchmed (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 219.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-07
Primary completion date: 2019-03-31
Completion date: 2022-07-07
Clinical trial NCT04077970: Intrauterine Flushing With Follicular Fluid Plus Granulosa Cells
Official title: Evaluation of Implantation and Clinical Pregnancy After Intrauterine Flushing of Infertile Patients With Follicular Fluid Plus Granulosa Cells- Randomized Controlled Trial
Sponsor: Royan Institute (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 140.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-01
Primary completion date: 2022-12-01
Completion date: 2023-01-01
Clinical trial NCT04009096: VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines
Official title: A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 16.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-07-18
Primary completion date: 2022-07-07
Completion date: 2022-07-07
Clinical trial NCT03766750: Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.
Official title: Randomized, Double-blind, Multicenter, National, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus
Sponsor: EMS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-31
Primary completion date: 2023-10-31
Completion date: 2023-11-30
Clinical trial NCT04680286: Intraoperative Methadone in Children Undergoing Surgery
Official title: The Use of Intraoperative Methadone in Children Undergoing Open Urological Surgery: a Randomized, Double-blind Trial
Acronym: METACEBO
Sponsor: University of Aarhus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Slow recruitment due to covid-19 and organizational changes.
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-16
Primary completion date: 2024-01-30
Completion date: 2024-02-01
Plan to share individual participant data: NO
Clinical trial NCT05046795: Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
Official title: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Nebulized Revefenacin Inhalation Solution in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).
Sponsor: Viatris Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 258.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-10
Primary completion date: 2023-07-26
Completion date: 2023-07-26
Plan to share individual participant data: NO